Cancers

Body mass index and outcomes in HR+/HER2- metastatic breast cancer treated with palbociclib: Insights from a national real-world study

Journal of Clinical Medicine

Is genetic testing of HER2-negative metastatic breast cancer patients implemented into clinical practice? A retrospective analysis

npj Breast Cancer

Imlunestrant with or without abemaciclib in advanced breast cancer: Safety analyses from the EMBER-3 trial

ESMO Open

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the phase III EMBER-3 trial

Lancet Regional Health

Real-world study of treatment patterns and outcomes in patients with HR+ breast cancer after progression on CDK4/6 inhibitor therapy

Annals of Oncology

Imlunestrant with or without abemaciclib in advanced breast cancer: Updated efficacy results from the phase III EMBER-3 trial

Cancer Treatment Reviews

Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis

Breast Cancer Research

Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors

Annals of Oncology

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: Final overall survival analysis of the phase 3 TROPION-Breast01 study

eLife

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer